Pacira BioSciences to Present at the 2020 BMO Prescriptions for Success Healthcare Conference
Pacira BioSciences, Inc. (NASDAQ: PCRX) will present at the 2020 BMO Prescriptions for Success Healthcare Conference on June 23, 2020, at 10:00 AM ET.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Pacira BioSciences, Inc. (NASDAQ: PCRX) will present at the 2020 BMO Prescriptions for Success Healthcare Conference on June 23, 2020, at 10:00 AM ET. Interested investors can access the live audio through the company’s website, with a replay available for two weeks post-event. Pacira specializes in non-opioid pain management and regenerative health solutions, with its flagship product, EXPAREL®, a long-acting analgesic launched in April 2012. The company aims to reduce opioid reliance and recently acquired the iovera⁰ system for targeted nerve pain management.
Details
News Market Reaction – PCRX
The recorded move for PCRX in the trading session of this news was +4.42%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
PARSIPPANY, N.J., June 16, 2020 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (NASDAQ: PCRX) today announced that it will present at the 2020 BMO Prescriptions for Success Healthcare Conference at 10:00 AM ET on Tuesday, June 23, 2020. Live audio of the virtual event can be accessed by visiting the “Events” page of the company’s website at investor.pacira.com. A replay of the webcast will also be available for two weeks following the event.
About Pacira
Pacira BioSciences, Inc. (NASDAQ: PCRX) is a leading provider of non-opioid pain management and regenerative health solutions dedicated to advancing and improving outcomes for health care practitioners and their patients. The company’s long-acting local analgesic, EXPAREL® (bupivacaine liposome injectable suspension) was commercially launched in the United States in April 2012. EXPAREL utilizes DepoFoam®, a unique and proprietary product delivery technology that encapsulates drugs without altering their molecular structure, and releases them over a desired period of time. In April 2019, the company acquired the iovera⁰ system, a handheld cryoanalgesia device used to deliver precise, controlled doses of cold temperature only to targeted nerves. To learn more about Pacira, including the corporate mission to reduce overreliance on opioids, visit www.pacira.com.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.